IL123248A0 - Ncv ns3 protein fragments having helicase activity and improved solubility - Google Patents

Ncv ns3 protein fragments having helicase activity and improved solubility

Info

Publication number
IL123248A0
IL123248A0 IL12324896A IL12324896A IL123248A0 IL 123248 A0 IL123248 A0 IL 123248A0 IL 12324896 A IL12324896 A IL 12324896A IL 12324896 A IL12324896 A IL 12324896A IL 123248 A0 IL123248 A0 IL 123248A0
Authority
IL
Israel
Prior art keywords
ncv
protein fragments
improved solubility
helicase activity
helicase
Prior art date
Application number
IL12324896A
Other languages
English (en)
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24108806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL123248(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of IL123248A0 publication Critical patent/IL123248A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12324896A 1995-09-15 1996-09-12 Ncv ns3 protein fragments having helicase activity and improved solubility IL123248A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/529,169 US6194140B1 (en) 1990-04-04 1995-09-15 HCV NS3 protein fragments having helicase activity and improved solubility
PCT/US1996/014688 WO1997012043A2 (en) 1995-09-15 1996-09-12 Hcv ns3 protein fragments having helicase activity and improved solubility

Publications (1)

Publication Number Publication Date
IL123248A0 true IL123248A0 (en) 1998-09-24

Family

ID=24108806

Family Applications (5)

Application Number Title Priority Date Filing Date
IL123248A IL123248A (en) 1995-09-15 1996-09-12 Preparations containing a section of HCV NS3 Helix
IL12324896A IL123248A0 (en) 1995-09-15 1996-09-12 Ncv ns3 protein fragments having helicase activity and improved solubility
IL171901A IL171901A (en) 1995-09-15 2005-11-10 A preparation containing a polynucleotide encoding a fusion protein containing a segment of HCV NS3 helicase
IL171900A IL171900A (en) 1995-09-15 2005-11-10 Vector expression to create active HCV NS3 HELICASE segments
IL171896A IL171896A0 (en) 1995-09-15 2005-11-10 Fusion protein comprising a hcv ns3 helicase fragment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL123248A IL123248A (en) 1995-09-15 1996-09-12 Preparations containing a section of HCV NS3 Helix

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL171901A IL171901A (en) 1995-09-15 2005-11-10 A preparation containing a polynucleotide encoding a fusion protein containing a segment of HCV NS3 helicase
IL171900A IL171900A (en) 1995-09-15 2005-11-10 Vector expression to create active HCV NS3 HELICASE segments
IL171896A IL171896A0 (en) 1995-09-15 2005-11-10 Fusion protein comprising a hcv ns3 helicase fragment

Country Status (8)

Country Link
US (4) US6194140B1 (ja)
EP (1) EP0850308A2 (ja)
JP (5) JPH11512606A (ja)
AU (1) AU717875B2 (ja)
CA (1) CA2226293C (ja)
IL (5) IL123248A (ja)
NZ (1) NZ319786A (ja)
WO (1) WO1997012043A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
CA2244372A1 (en) * 1996-01-23 1997-07-31 Marc S. Collett Methods for identifying inhibitors of rna viruses
US6183121B1 (en) * 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
CZ298268B6 (cs) * 1998-04-17 2007-08-08 Innogenetics N. V. Imunodiagnostický test používající redukující cinidla
CA2369384A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. Prostate-restricted gene 30p3c8 expressed in prostate cancer
MXPA02012424A (es) 2000-06-15 2003-04-25 Chiron Corp Ensayo de combinacion de antigenos/anticuerpos para el virus de hepatitis c.
EP1829891B1 (en) * 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Immunoassays for Anti-HCV Antibodies
AU9215101A (en) * 2000-08-17 2002-02-25 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
KR100390371B1 (ko) * 2000-08-17 2003-07-07 제노프라 주식회사 C형 간염 바이러스 증식조절단백질에 특이적으로 결합하는 rna 및 이를 이용한 hcv 감염 진단용 키트
WO2002070752A1 (en) * 2001-02-14 2002-09-12 The Regents Of The University Of California Assay for hepatitis c virus helicase (ns3) rna binding
DE10123041A1 (de) * 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
ITRM20010336A1 (it) * 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2004106517A1 (en) * 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded nucleic acid
EP2363483A3 (en) * 2004-03-05 2014-07-16 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン,インコーポレイテッド 慢性c型肝炎ウイルス感染の免疫療法
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
EP2968526A4 (en) 2013-03-14 2016-11-09 Abbott Lab ANTIGEN-ANTIBODY COMBINATION ASSAY OF HEPATITIS C VIRUS AND METHODS AND COMPOSITIONS FOR USE THEREWITH
WO2014143342A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US10088483B2 (en) * 2014-10-29 2018-10-02 Abbott Laboratories Subject anti-HCV antibody detection assays employing NS3 capture peptides
KR101784455B1 (ko) * 2015-12-04 2017-10-11 주식회사 바이오노트 C형 간염 바이러스의 친수성 단편을 포함하는 융합 폴리펩티드, 그를 포함하는 c형 간염 바이러스 감염을 진단하기 위한 조성물, 키트, 및 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3563848D1 (en) 1984-04-06 1988-08-25 Zambon Spa Process for the preparation of optically active alpha-arylalkanoic acids and intermediates thereof
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
ATE433460T1 (de) 1990-04-04 2009-06-15 Novartis Vaccines & Diagnostic Protease von hepatitis c virus
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
JPH06319583A (ja) 1992-09-18 1994-11-22 Souyaku Gijutsu Kenkyusho:Kk C型肝炎ウイルスがコードするへリカーゼ領域の製造方法

Also Published As

Publication number Publication date
AU7238496A (en) 1997-04-17
JP2007300933A (ja) 2007-11-22
IL171901A0 (en) 2006-04-10
AU717875B2 (en) 2000-04-06
IL123248A (en) 2007-07-24
NZ319786A (en) 2000-01-28
US6194140B1 (en) 2001-02-27
US6472180B1 (en) 2002-10-29
WO1997012043A3 (en) 1997-09-25
JP2010235609A (ja) 2010-10-21
JP2006271388A (ja) 2006-10-12
IL171900A (en) 2012-12-31
JP2004147661A (ja) 2004-05-27
IL171896A0 (en) 2006-04-10
IL171900A0 (en) 2006-04-10
EP0850308A2 (en) 1998-07-01
IL171901A (en) 2012-12-31
JPH11512606A (ja) 1999-11-02
US5989905A (en) 1999-11-23
US7033805B2 (en) 2006-04-25
CA2226293A1 (en) 1997-04-03
WO1997012043A2 (en) 1997-04-03
US20030129586A1 (en) 2003-07-10
CA2226293C (en) 2002-07-30

Similar Documents

Publication Publication Date Title
IL123248A0 (en) Ncv ns3 protein fragments having helicase activity and improved solubility
PL336420A1 (en) Improved methods of processing activated protein c
EP0785276A4 (en) MODIFICATION OF A PEPTIDE AND A PROTEIN
ZA964733B (en) Ob protein compositions and methods
GB2338237B (en) In vitro peptide or protein expression library
IL134699A0 (en) Protein composition and process for isolating a protein composition from a muscle source
HUP0004617A3 (en) Antistress agents and functional foods
GB9718520D0 (en) Functional protein concentrates and isolates
IL118375A0 (en) Rhesus OB protein and DNA
EP1083915A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING PROTEIN ANABOLISM AND DETOXICATION
GB9516059D0 (en) Novel genes and proteins
EP0950663A4 (en) USEFUL PROTEIN STABILIZATION AND USEFUL PROTEIN COMPOSITIONS
GB9510830D0 (en) Proteins
GB9614033D0 (en) Modified protein G and fragments thereof
GB9918155D0 (en) Proteins and peptides
EP1038958A4 (en) HUMAN NAP1 PROTEIN
HUP9602914A2 (en) Method of inactivating viruses in proteins
GB9715064D0 (en) Protein expression
GB9519865D0 (en) Protein
EP1161147A4 (en) PEPTIDE MIMETICS USEFUL FOR TREATING DISEASES
GB9622436D0 (en) Protein
EP1142999A4 (en) PROTEIN AND ITS DNA
EP0984065A4 (en) MODIFIED PROTEINANTIGENT FROM TREPONEMA PALLADIUM.
GB9310227D0 (en) Protein and dna
EP1111047A4 (en) NEW PROTEIN AND ITS DNA

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed